Published in Arch Biochem Biophys on January 15, 2003
Serpin Inhibition Mechanism: A Delicate Balance between Native Metastable State and Polymerization. J Amino Acids (2011) 0.83
Multiple domains of endopin 2A for serpin cross-class inhibition of papain. Arch Biochem Biophys (2007) 0.80
Anti-serpin antibody-mediated regulation of proteases in autoimmune diabetes. J Biol Chem (2012) 0.79
Enhanced anti-serpin antibody activity inhibits autoimmune inflammation in type 1 diabetes. J Immunol (2012) 0.79
Human SERPINB12 Is an Abundant Intracellular Serpin Expressed in Most Surface and Glandular Epithelia. J Histochem Cytochem (2015) 0.78
SERPINB13 is a novel RUNX1 target gene. Biochem Biophys Res Commun (2011) 0.76
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 6.53
American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol (2006) 2.68
KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.55
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
An overview of the serpin superfamily. Genome Biol (2006) 2.14
Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J Biol Chem (2006) 2.05
Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem Rev (2002) 1.81
Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin α1-antitrypsin Z. PLoS One (2010) 1.62
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis (2005) 1.61
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol (2007) 1.61
BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res (2004) 1.58
An intracellular serpin regulates necrosis by inhibiting the induction and sequelae of lysosomal injury. Cell (2007) 1.56
The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev (2005) 1.47
Human tracheal reconstruction with a composite radial forearm free flap and prosthesis. Ann Thorac Surg (2006) 1.46
Regulation of collagenase activities of human cathepsins by glycosaminoglycans. J Biol Chem (2003) 1.46
Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer (2004) 1.43
Small molecule affinity fingerprinting. A tool for enzyme family subclassification, target identification, and inhibitor design. Chem Biol (2002) 1.42
CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci U S A (2009) 1.35
Pivotal role of cathepsin K in lung fibrosis. Am J Pathol (2004) 1.35
Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum (2002) 1.34
Serpins flex their muscle: I. Putting the clamps on proteolysis in diverse biological systems. J Biol Chem (2010) 1.32
A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J Biol Chem (2006) 1.31
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res (2004) 1.30
High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res (2009) 1.29
Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope (2005) 1.27
Elective and therapeutic selective neck dissection. Oral Oncol (2005) 1.26
Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest (2014) 1.26
Cathepsin V, a novel and potent elastolytic activity expressed in activated macrophages. J Biol Chem (2004) 1.24
Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann Surg Oncol (2011) 1.23
Monitoring compartment-specific substrate cleavage by cathepsins B, K, L, and S at physiological pH and redox conditions. BMC Biochem (2009) 1.21
Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer (2011) 1.21
Gene-environment interaction involved in oral carcinogenesis: molecular epidemiological study for metabolic and DNA repair gene polymorphisms. J Oral Pathol Med (2006) 1.19
Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. J Invest Dermatol (2007) 1.19
An orthotopic model of papillary thyroid carcinoma in athymic nude mice. Arch Otolaryngol Head Neck Surg (2008) 1.19
Inhibitory activity of a heterochromatin-associated serpin (MENT) against papain-like cysteine proteinases affects chromatin structure and blocks cell proliferation. J Biol Chem (2002) 1.17
Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck (2009) 1.17
Biochemical properties and regulation of cathepsin K activity. Biochimie (2007) 1.15
Identification of 9 genes differentially expressed in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2003) 1.15
Serpins flex their muscle: II. Structural insights into target peptidase recognition, polymerization, and transport functions. J Biol Chem (2010) 1.14
Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. J Biol Chem (2008) 1.14
The crystal and molecular structures of a cathepsin K:chondroitin sulfate complex. J Mol Biol (2008) 1.14
Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities. Am J Pathol (2009) 1.13
p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res (2003) 1.13
Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin Cancer Res (2004) 1.13
Update of the human and mouse SERPIN gene superfamily. Hum Genomics (2013) 1.12
Serine protease activity contributes to control of Mycobacterium tuberculosis in hypoxic lung granulomas in mice. J Clin Invest (2010) 1.11
Selective inhibition of the collagenolytic activity of human cathepsin K by altering its S2 subsite specificity. Biochemistry (2002) 1.10
Recent advances in thyroid cancer. Curr Probl Surg (2008) 1.09
Potent and broad-spectrum antimicrobial activity of CXCL14 suggests an immediate role in skin infections. J Immunol (2009) 1.09
MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther (2010) 1.08
Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J Invest Dermatol (2006) 1.08
A prospective study of intraoperative lymphatic mapping for head and neck cutaneous melanoma. Arch Otolaryngol Head Neck Surg (2002) 1.08
Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther (2013) 1.08
Parathyroid carcinoma: a 22-year experience. Head Neck (2004) 1.08
Modeling molecular and cellular aspects of human disease using the nematode Caenorhabditis elegans. Pediatr Res (2009) 1.07
Hepatic fibrosis and carcinogenesis in α1-antitrypsin deficiency: a prototype for chronic tissue damage in gain-of-function disorders. Cold Spring Harb Perspect Biol (2011) 1.07
Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res (2006) 1.06
Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res (2011) 1.03
Reduced DNA repair capacity for removing tobacco carcinogen-induced DNA adducts contributes to risk of head and neck cancer but not tumor characteristics. Clin Cancer Res (2010) 1.02
TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation. Cancer Res (2009) 1.02
Predictors of level V metastasis in well-differentiated thyroid cancer. Head Neck (2008) 1.01
SPINK5 and Netherton syndrome: novel mutations, demonstration of missing LEKTI, and differential expression of transglutaminases. J Invest Dermatol (2004) 1.01
Cleavage site specificity of cathepsin K toward cartilage proteoglycans and protease complex formation. Biol Chem (2003) 1.00
NF-kappaB protects from the lysosomal pathway of cell death. EMBO J (2003) 1.00
Defective feedback regulation of NF-kappaB underlies Sjogren's syndrome in mice with mutated kappaB enhancers of the IkappaBalpha promoter. Proc Natl Acad Sci U S A (2010) 1.00
Peripheral osteoma of the mandibular notch: report of a case. Iran J Radiol (2013) 1.00
Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. Clin Cancer Res (2007) 0.99
Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors. Biochemistry (2002) 0.99
Simultaneous reconstruction of the posterior pharyngeal wall and cervical spine with a free vascularized fibula osteocutaneous flap. Plast Reconstr Surg (2002) 0.98
Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther (2003) 0.98
Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells. Clin Cancer Res (2013) 0.98
Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI). Biol Chem (2005) 0.98
Effects of cysteine proteases on the structural and mechanical properties of collagen fibers. J Biol Chem (2013) 0.98
A pro-cathepsin L mutant is a luminal substrate for endoplasmic-reticulum-associated degradation in C. elegans. PLoS One (2012) 0.97
The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases. Biochemistry (2002) 0.97
Inhibition of serine proteinases plasmin, trypsin, subtilisin A, cathepsin G, and elastase by LEKTI: a kinetic analysis. Biochemistry (2003) 0.96
Evidence that serpin architecture intrinsically supports papain-like cysteine protease inhibition: engineering alpha(1)-antitrypsin to inhibit cathepsin proteases. Biochemistry (2002) 0.96